HST Global, Inc.

Equities

HSTC

US40432E2028

Biotechnology & Medical Research

Delayed OTC Markets Other stock markets 18:31:15 21/05/2024 BST			5-day change	1st Jan Change
1.08 ^USD	-1.82%		-1.82%	+77.78%

04-05	HST Global, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	HST Global, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI

Hst Global, Inc. Reports Earnings Results for the Full Year Ended December 31, 2018

April 02, 2019 at 11:21 am

HST Global, Inc. announced earnings results for the full year ended December 31, 2018. For the full year, the company announced operating loss was USD 142,587 compared to USD 152,995 a year ago. Net loss was USD 178,335 compared to USD 165,092 a year ago.

Latest news about HST Global, Inc.

HST Global, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	04-05	CI
HST Global, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-07	CI
HST Global, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	11/08/23	CI
HST Global, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	12/05/23	CI
HST Global, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	31/01/23	CI
HST Global, Inc. Auditor Raises 'Going Concern' Doubt	30/01/23	CI
HST Global, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	04/11/22	CI
HST Global, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	26/07/22	CI
HST Global, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	29/04/22	CI
HST Global, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	04/03/22	CI
HST Global, Inc. Auditor Raises 'Going Concern' Doubt	03/03/22	CI
HST Global, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	08/11/21	CI
Hst Global, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021	13/08/21	CI
Hst Global, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021	13/05/21	CI
HST Global, Inc. Reports Earnings Results for the Full Year Ended December 31, 2020	14/04/21	CI
HST Global, Inc. Auditor Raises 'Going Concern' Doubt	13/04/21	CI
Hst Global, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020	13/11/20	CI
Hst Global, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2020	10/08/20	CI
Hst Global, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020	15/05/20	CI
Hst Global, Inc. Reports Earnings Results for the Full Year Ended December 31, 2019	09/04/20	CI
Hst Global, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019	19/11/19	CI
Hst Global, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2019	20/08/19	CI
Hst Global, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2019	16/05/19	CI
Hst Global, Inc. Reports Earnings Results for the Full Year Ended December 31, 2018	02/04/19	CI
HST Global, Inc. Auditor Raises 'Going Concern' Doubt	19/03/15	CI

Chart HST Global, Inc.

Duration

Period

More charts

Company Profile

HST Global, Inc. is an integrated health and wellness biotechnology company. The Company is focused on developing and /or acquiring a network of wellness centers worldwide that is primarily focused on the homeopathic and alternative treatment of late-stage cancer. The Company intends to acquire innovative products for the treatment of life-threatening diseases. The Company primarily focuses on homeopathic and alternative product candidates that are undergoing or have already completed clinical testing for the treatment of late-stage cancer and/or life-threatening diseases. The Company has not generated any revenue.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
HST GLOBAL, INC.	+77.78%	44.89M
MODERNA, INC.	+51.25%	63.85B
IQVIA HOLDINGS INC.	-2.44%	41.83B
LONZA GROUP AG	+40.01%	40.47B
CELLTRION, INC.	-10.22%	27.17B
ICON PUBLIC LIMITED COMPANY	+13.48%	26.52B
ALNYLAM PHARMACEUTICALS, INC.	-20.71%	18.69B
BIO-TECHNE CORPORATION	+2.93%	12.73B
UNITED THERAPEUTICS CORPORATION	+22.12%	12.11B
MEDPACE HOLDINGS, INC.	+27.76%	12.07B

Other Biotechnology & Medical Research